Omeros Corp 8-K Filing
Ticker: OMER · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1285819
| Field | Detail |
|---|---|
| Company | Omeros Corp (OMER) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Omeros Corp (ticker: OMER) to the SEC on Dec 29, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (nge on which registered Common stock , $0.01 par value per share OMER The Nasdaq).
How long is this filing?
Omeros Corp's 8-K filing is 2 pages with approximately 520 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-29 06:08:56
Key Financial Figures
- $0.01 — nge on which registered Common stock , $0.01 par value per share OMER The Nasdaq
Filing Documents
- omer20251218_8k.htm (8-K) — 28KB
- ex_902630.htm (EX-99.1) — 46KB
- omeroslogo_2.jpg (GRAPHIC) — 7KB
- 0001437749-25-038758.txt ( ) — 223KB
- omer-20251224.xsd (EX-101.SCH) — 3KB
- omer-20251224_def.xml (EX-101.DEF) — 11KB
- omer-20251224_lab.xml (EX-101.LAB) — 15KB
- omer-20251224_pre.xml (EX-101.PRE) — 11KB
- omer20251218_8k_htm.xml (XML) — 3KB
.01. Other Events
Item 8 .01. Other Events. On December 24, 2025, Omeros Corporation (the "Company" or "we") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. A revised version of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The December 24, 2025 press release was revised to reflect the new date for the YARTEMLEA approval-related conference call and to provide supplemental information regarding the experts quoted in the press release. No other changes were made.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated December 24, 2025 (as revised) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OMEROS CORPORATION Date: December 29, 2025 By: /s/ Gregory A. Demopulos Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors 3